The precise MHRA label scope has not been confirmed from a primary regulator source
Although both medications share the same active ingredient, they are marketed with different applications and dosages, emphasizing the importance of following a healthcare providers guidance when considering these treatments for diabetes or weight management
This happens faster with the right care and diet changes
For detailed information about what to expect throughout your entire treatment journey, see our complete guide to semaglutide weight loss results month by month
This month, the CEO of Novo Nordisk, Lars Fruergaard Jorgensen, appeared before the United States Senate Committee on Health, Education, Labor, and Pensions
Clinical trials have shown that semaglutide can decrease the risk of major cardiovascular events or death by 26% in people with diabetes